These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 21062241)
1. Cancer vaccines in phase II/III clinical trials: state of the art and future perspectives. Cecco S; Muraro E; Giacomin E; Martorelli D; Lazzarini R; Baldo P; Dolcetti R Curr Cancer Drug Targets; 2011 Jan; 11(1):85-102. PubMed ID: 21062241 [TBL] [Abstract][Full Text] [Related]
2. Cancer vaccines entering Phase III clinical trials. Durrant LG; Spendlove I Expert Opin Emerg Drugs; 2003 Nov; 8(2):489-500. PubMed ID: 14662001 [TBL] [Abstract][Full Text] [Related]
3. Cancer vaccines: on the threshold of success. Emens LA Expert Opin Emerg Drugs; 2008 Jun; 13(2):295-308. PubMed ID: 18537522 [TBL] [Abstract][Full Text] [Related]
4. Cancer vaccines: Where are we going? Cebon J Asia Pac J Clin Oncol; 2010 Mar; 6 Suppl 1():S9-15. PubMed ID: 20482531 [TBL] [Abstract][Full Text] [Related]
5. Cancer vaccines: what do we need to measure in clinical trials? Kudrin A Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508 [TBL] [Abstract][Full Text] [Related]
6. Cancer vaccines: translation from mice to human clinical trials. Maeng H; Terabe M; Berzofsky JA Curr Opin Immunol; 2018 Apr; 51():111-122. PubMed ID: 29554495 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic cancer vaccines: From initial findings to prospects. Song Q; Zhang CD; Wu XH Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608 [TBL] [Abstract][Full Text] [Related]
8. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Seremet T; Brasseur F; Coulie PG Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282 [TBL] [Abstract][Full Text] [Related]
9. Promises and limitations of murine models in the development of anticancer T-cell vaccines. Lévy F; Colombetti S Int Rev Immunol; 2006; 25(5-6):269-95. PubMed ID: 17169777 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic cancer vaccines based on molecularly defined human tumor antigens. Romero P; Pittet M; Dutoit V; Zippelius A; Liénard D; Lejeune F; Guillaume P; Rimoldi D; Valmori D; Speiser DE; Cerottini JC Vaccine; 2002 Dec; 20 Suppl 4():A2-7. PubMed ID: 12477422 [TBL] [Abstract][Full Text] [Related]